The role of nesiritide in heart failure

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 7, 2009, Pages 823-834

  Tong, Ann T ^a   Rozner, Marc A ^b,c  

^a UNITED HEALTHCARE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Acute decompensated heart failure; Left ventricular dysfunction; Natriuretic agents; Nesiritide; Vasodilator

Indexed keywords

AMRINONE; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; LEVOSIMENDAN; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; PLACEBO;

ACUTE DECOMPENSATED HEART FAILURE; ARTERY STEAL SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE OXYGEN CONSUMPTION; HEART SURGERY; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG ARTERY PRESSURE; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; TACHYCARDIA; TACHYPHYLAXIS;

ANIMALS; HEART FAILURE; HUMANS; LENGTH OF STAY; NATRIURETIC PEPTIDE, BRAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67650729798     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903042300     Document Type: Review

References (61)

1. American Heart Association. Heart Disease and Stroke Statistics - 2008 Update. American Heart Association. Published 2008. Dallas, TX. Available from: http://www.americanheart.org/ downloadable/heart/1200082005246HS- Stats%202008.final.pdf. [Accessed 2 March 2009]
2. Nicholls DP, Onuoha GN, McDowell G, et al. Neuroendocrine changes in chronic cardiac failure. Basic Res Cardiol 1996;91(Suppl 1):13-20 (Pubitemid 26332150)
3. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149(2):209-216 (Pubitemid 40348525)
4. Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med 2002;3(Suppl 4):S3-9
5. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med 2002;162(15):1689-1694 (Pubitemid 34894797)
6. Fonarow GC, Adams KF Jr, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005;293(5):572-580 (Pubitemid 40171239)
7. Shahar E, Lee S, Kim J, et al. Hospitalized heart failure: rates and long-term mortality. J Card Fail 2004;10(5):374-379 (Pubitemid 41080216)
8. Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. Rev Cardiovasc Med 2001;2(Suppl 2):S2-6
9. Burnett JC Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl 1999;17(1):S37-43
10. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007;49(10):1071-1078 (Pubitemid 46349497)
11. Abassi Z, Karram T, Ellaham S, et al. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther 2004;102(3):223-241 (Pubitemid 38887694)
12. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 2002;105(11):1348-1353 (Pubitemid 34260427)
13. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103(1):1-6
14. Kelly RA, Wilcox CS, Mitch WE, et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int 1983;24(2):233-239
15. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288(20):2547- 2553 (Pubitemid 35386889)
16. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999;19(6):581-597
17. Burger AJ, Aronson D. Activity of the neurohormonal system and its relationship to autonomic abnormalities in decompensated heart failure. J Card Fail 2001;7(2):122-128 (Pubitemid 32554105)
18. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991;325(21):1468-1475
19. Burger AJ, Elkayam U, Neibaur MT, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88(1):35-39 (Pubitemid 32553889)
20. Gruhn N, Nielsen-Kudsk JE, Theilgaard S, et al. Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 1998;31(5):741-749 (Pubitemid 28217595)
21. Lilleberg J, Sundberg S, Hayha M, et al. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994;47(3):267-274 (Pubitemid 24330669)
22. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297(17):1883-1891 (Pubitemid 46707842)
23. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46(1):57-64 (Pubitemid 40905130)
24. Peacock WF, Emerman CL, Young J. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. J Card Fail 2004;10(2):120-125 (Pubitemid 38858072)
25. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med 2002;3(Suppl 4):S18-S27
26. Elkayam U, Akhter MW, Tummala P, et al. Nesiritide: a new drug for the treatment of decompensated heart failure. J Cardiovasc Pharmacol Ther 2002;7(3):181-194 (Pubitemid 36055999)
27. Persson H, Lonn E, Edner M, et al. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 2007;49(6):687-694 (Pubitemid 46205045)
28. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343(4):246-253 In patients hospitalized with decompensated congestive heart failure, nesiritide improves hemodynamic function and clinical status. (Pubitemid 30490392)
29. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998;4(1):37-44 (Pubitemid 28252539)
30. Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37(5):1221-1227 (Pubitemid 32295578)
31. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol 2002;90(4):435-438 (Pubitemid 34895071)
32. Scios, Incorporated. Natrecor (nesiritide) intravenous B-type natriuretic peptide (BNP) for injection. Prescribing Information. Document 20030306, Revised Jan 2007. Published 2007. Mountain View, CA. Available from: http://www.natrecor.com/natrecor/ assets/pdf/natrecor-pi.pdf. [Accessed 2 March 2009]
33. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287(12):1531-1540 •• When added to standard care in patients hospitalized with acutely decompensated CHF, nesiritide improves hemodynamic function and some self-reported symptoms more effectively than intravenous nitroglycerin or placebo
34. Boerrigter G, Burnett JC Jr. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs 2004;13(6):643-652 (Pubitemid 38868054)
35. Mills RM, LeJemtel TH, Horton DP, et al. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999;34(1):155-62 • The rapid and sustained beneficial hemodynamic effects of nesiritide observed in this study support its use as a first-line i.v. therapy for patients with symptomatic decompensated HF.
36. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144(6):1102-1108 Dobutamine is associated with substantial proarrhythmic and chronotropic effects in patients with decompensated CHF, whereas nesiritide actually reduces ventricular ectopy or has a neutral effect. Compared with dobutamine, nesiritide may be a safer, short-term treatment for patients with decompensated CHF. (Pubitemid 36026926)
37. Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med 2005;23(3):327-331 Early administration of nesiritide in the emergency department provides safe and effective treatment of heart failure. (Pubitemid 40732268)
38. Ezekowitz JA, Hernandez AF, Starling RC, et al. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). Am Heart J 2009;157(2):219-228
39. Hernandez AF, O'Connor CM, Starling RC, et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 2009;157(2):271-277
40. Yoshimura M, Yasue H, Morita E, et al. Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991;84(4):1581-1588
41. van der Zander K, Houben AJ, Hofstra L, et al. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am J Physiol Heart Circ Physiol 2003;285(3):H1206-12 (Pubitemid 37048178)
42. Heywood JT, Fonarow GC, Costanzo MR, et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13(6):422-430 (Pubitemid 47179911)
43. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111(12):1487-1491 Nesiritide significantly increases the risk of worsening renal function in patients with ADHF. Whether worsening renal function reflects hemodynamic effect or renal injury is unknown, but the prognostic importance of worsening renal function suggests the need for further investigation in appropriately powered clinical trials. (Pubitemid 40470642)
44. Heywood JT. Temporal characteristics of serum creatinine elevations in patients receiving nesiritide and nitroglycerin. J Card Fail 2005;11(6):S158
45. Burger AJ. Risk of death with nesiritide. JAMA 2005;294(8):897
46. Riter HG, Redfield MM, Burnett JC, Chen HH. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 2006;47(11):2334-2335 (Pubitemid 43795074)
47. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293(15):1900-5 Compared with noninotrope-based control therapy, nesiritide may be associated with an increased risk of death after treatment for acutely decompensated heart failure. The possibility of an increased risk of death should be investigated in a large-scale, adequately powered, controlled trial before routine use of nesiritide for acutely decompensated heart failure. (Pubitemid 40548187)
48. Gortney JS, Porter KB. Risk of death with nesiritide. JAMA 2005;294(8):897-898
49. Abraham WT. Nesiritide does not increase 30-day or 6-month mortality risk. Circulation 2005;112(17 Suppl II)
50. Arora RR, Venkatesh PK, Molnar J. Short and long-term mortality with nesiritide. Am Heart J 2006;152(6):1084-1090
51. Yancy CW, Saltzberg MT, Berkowitz RL, et al. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial). Am J Cardiol 2004;94(5):595-601 (Pubitemid 39165837)
52. Yancy CW, Krum H, Massie BM, et al. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the second Follow-Up Serial Infusions of Nesiritide (FUSION II) Trial. Circ Heart Fail 2008;1(1):9-16
53. Samuels LE, Holmes EC, Lee L. Nesiritide as an adjunctive therapy in adult patients with heart failure undergoing high-risk cardiac surgery. J Thorac Cardiovasc Surg 2004;128(4):627-629 (Pubitemid 39278403)
54. Gordon GR, Schumann R, Rastegar H, et al. Nesiritide for treatment of perioperative low cardiac output syndromes in cardiac surgical patients: an initial experience. J Anesth 2006;20(4):307-311 (Pubitemid 44650714)
55. Chen HH, Sundt TM, Cook DJ, et al. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: a double-blind placebo-controlled pilot study. Circulation 2007;116(11 Suppl):I-134-138 (Pubitemid 47480781)
56. Feldman DS, Ikonomidis JS, Uber WE, et al. Human B-natriuretic peptide improves hemodynamics and renal function in heart transplant patients immediately after surgery. J Card Fail 2004;10(4):292-296 (Pubitemid 39092679)
57. Salzberg SP, Filsoufi F, Anyanwu A, et al. High-risk mitral valve surgery: perioperative hemodynamic optimization with nesiritide (BNP). Ann Thorac Surg 2005;80(2):502-506 (Pubitemid 41019468)
58. Mentzer RM Jr, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 2007;49(6):716-726 Nesiritide in the setting of CABG with CPB is associated with improved postoperative renal function and possibly enhanced survival. (Pubitemid 46205038)
59. Braunwald E, Burnett JC Jr, Colucci WS, et al. Natrecor panel report. Medwatch. Published 13 June 2005. Available from: http: //www.fda.gov/medWatch/ safety/2005/natrecor2-DHCP.htm. [Accessed 1 March 2009] •• Expert panel recommendations for the use of nesiritide.
60. Adams KF, Lindenfeld J, Arnold JMO, et al. HFSA 2006 Comprehensive heart failure practice guideline. J Card Fail 2006;12:e1-119 •• The 2006 Heart Failure Society of America comprehensive practice guideline addressing the full range of evaluation, care, and management of patients with HF.
61. Lee CY, Burnett JC Jr. Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007;12(2):131-142